Your browser doesn't support javascript.
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
Sanders, Jan-Stephan F; Bemelman, Frederike J; Messchendorp, A Lianne; Baan, Carla C; van Baarle, Debbie; van Binnendijk, Rob; Diavatopoulos, Dimitri A; Frölke, Sophie C; Geers, Daryl; GeurtsvanKessel, Corine H; den Hartog, Gerco; van der Heiden, Marieke; Imhof, Celine; Kho, Marcia M L; Koopmans, Marion P G; Malahe, S Reshwan K; Mattheussens, Wouter B; van der Molen, Renate; van Mourik, Djenolan; Remmerswaal, Ester B M; Rots, Nynke; Vart, Priya; de Vries, Rory D; Gansevoort, Ron T; Hilbrands, Luuk B; Reinders, Marlies E J.
  • Sanders JF; Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Bemelman FJ; Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Messchendorp AL; Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Baan CC; Department of Internal Medicine, Nephrology, and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Baarle D; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands.
  • van Binnendijk R; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Diavatopoulos DA; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Frölke SC; Radboud Center for Infectious Diseases, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
  • Geers D; Radboud Institute for Molecular Life Sciences, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
  • GeurtsvanKessel CH; Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • den Hartog G; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van der Heiden M; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Imhof C; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Kho MML; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands.
  • Koopmans MPG; Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Malahe SRK; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands.
  • Mattheussens WB; Department of Internal Medicine, Nephrology, and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van der Molen R; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Mourik D; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Remmerswaal EBM; Department of Nephrology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Rots N; Radboud Institute for Molecular Life Sciences, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
  • Vart P; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
  • de Vries RD; Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Gansevoort RT; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Hilbrands LB; Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Reinders MEJ; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
Transplantation ; 106(4): 821-834, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1511132
ABSTRACT

BACKGROUND:

In kidney patients COVID-19 is associated with severely increased morbidity and mortality. A comprehensive comparison of the immunogenicity, tolerability, and safety of COVID-19 vaccination in different cohorts of kidney patients and a control cohort is lacking.

METHODS:

This investigator driven, prospective, controlled multicenter study included 162 participants with chronic kidney disease (CKD) stages G4/5 (eGFR < 30 mL/min/1.73m2), 159 participants on dialysis, 288 kidney transplant recipients, and 191 controls. Participants received 2 doses of the mRNA-1273 COVID-19 vaccine (Moderna). The primary endpoint was seroconversion.

RESULTS:

Transplant recipients had a significantly lower seroconversion rate when compared with controls (56.9% versus 100%, P < 0.001), with especially mycophenolic acid, but also, higher age, lower lymphocyte concentration, lower eGFR, and shorter time after transplantation being associated with nonresponder state. Transplant recipients also showed significantly lower titers of neutralizing antibodies and T-cell responses when compared with controls. Although a high seroconversion rate was observed for participants with CKD G4/5 (100%) and on dialysis (99.4%), mean antibody concentrations in the CKD G4/5 cohort and dialysis cohort were lower than in controls (2405 [interquartile interval 1287-4524] and 1650 [698-3024] versus 3186 [1896-4911] BAU/mL, P = 0.06 and P < 0.001, respectively). Dialysis patients and especially kidney transplant recipients experienced less systemic vaccination related adverse events. No specific safety issues were noted.

CONCLUSIONS:

The immune response following vaccination in patients with CKD G4/5 and on dialysis is almost comparable to controls. In contrast, kidney transplant recipients have a poor response. In this latter, patient group development of alternative vaccination strategies are warranted.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Transplantation Year: 2022 Document Type: Article Affiliation country: TP.0000000000003983

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Kidney Transplantation / Renal Insufficiency, Chronic / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Transplantation Year: 2022 Document Type: Article Affiliation country: TP.0000000000003983